瑞芬太尼仿制药MR13A11A用于日本ICU患者疼痛管理的疗效、安全性和药代动力学:双盲、芬太尼对照、随机、非劣效性3期研究
这项多中心、随机、双盲、芬太尼对照、非劣效性3期研究纳入年龄≥20岁、需在ICU机械通气6小时至10天且需镇痛的日本患者,1:1随机接受瑞芬太尼(n=98)或芬太尼(n=98),从1 mL/h(瑞芬太尼0.025 µg/kg/min,芬太尼0.1 µg/kg/h)起始,以1 mL/h递增至行为疼痛量表(BPS)≤5或数字评定量表(NRS)≤3的镇痛目标,随后调整维持至脱机。主要终点为未使用补救芬太尼的患者比例,瑞芬太尼组100%(92/92) vs 芬太尼组97.8%(88/90),差值2.2%(95%CI -0.8-5.3),非劣效性成立(p<0.0001)。两组任何不良事件发生率分别为37.0%(34/92)和37.8%(34/90),药物不良反应分别为13.0%(12/92)和16.7%(15/90)。24例患者动脉血药代动力学分析显示,停药后10分钟内瑞芬太尼血药浓度降至给药结束时的近50%,提示起效消退迅速。结论认为瑞芬太尼可安全用于日本ICU机械通气患者的疼痛管理。
要点
- 瑞芬太尼仿制药MR13A11A从0.025 µg/kg/min起始,按1 mL/h递增至BPS≤5或NRS≤3,未用补救芬太尼比例100%(92/92) vs 芬太尼97.8%(88/90),差值2.2%(95%CI -0.8-5.3),非劣效性p<0.0001。
- 两组任何不良事件发生率相似:瑞芬太尼37.0%(34/92) vs 芬太尼37.8%(34/90);药物不良反应13.0%(12/92) vs 16.7%(15/90)。
- 药代动力学亚组24例显示,停药后10分钟内瑞芬太尼血药浓度降至给药结束时的近50%,提示停药后作用消退迅速。
- 研究纳入年龄≥20岁、需机械通气6小时至10天且需镇痛的ICU患者,排除了不符合该条件的患者。
适用人群与场景
- 年龄≥20岁、需要在ICU接受6小时至10天机械通气且需要疼痛缓解的日本患者。
诊断标准与关键阈值
- 镇痛目标:行为疼痛量表(BPS)≤5或数字评定量表(NRS)≤3。
处置流程与药物剂量
- 瑞芬太尼从1 mL/h(0.025 µg/kg/min)起始,芬太尼从1 mL/h(0.1 µg/kg/h)起始,以1 mL/h递增至BPS≤5或NRS≤3的镇痛目标,随后调整剂量维持该目标直至脱机。
研究设计与关键结果
- 多中心、随机、双盲、芬太尼对照、非劣效性3期研究,瑞芬太尼组n=98、芬太尼组n=98;主要终点未用补救芬太尼比例瑞芬太尼100%(92/92) vs 芬太尼97.8%(88/90),差值2.2%(95%CI -0.8-5.3),非劣效性成立(p<0.0001)。
- 任何不良事件:瑞芬太尼34/92(37.0%) vs 芬太尼34/90(37.8%);药物不良反应:瑞芬太尼12/92(13.0%) vs 芬太尼15/90(16.7%)。
- 药代动力学分析(24例)显示,停药后10分钟内瑞芬太尼血药浓度降至给药结束时的近50%,提示停药后作用消退迅速。
证据类型、等级与局限
- 证据类型:多中心、随机、双盲、芬太尼对照、非劣效性3期研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为瑞芬太尼可安全用于日本ICU机械通气患者的疼痛管理。
指南或共识出处
- 日本临床试验注册库jRCT2080224954,注册日期2019年11月20日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The aims of this study were to evaluate the efficacy, safety, and pharmacokinetics (PK) of continuous intravenous administration of remifentanil in mechanically ventilated patients in the intensive care unit (ICU).
METHODS: This was a multicenter, randomized, double-blinded, fentanyl-controlled, non-inferiority phase 3 study. Patients aged ≥ 20 years requiring 6 h to 10 days mechanical ventilation in an ICU and requiring pain relief were randomly assigned in a 1:1 ratio to receive either remifentanil (n = 98) or fentanyl (n = 98). Dose was titrated from an infusion rate of 1 mL/h (remifentanil: 0.025 µg/kg/min, fentanyl: 0.1 µg/kg/h) until the target level of analgesia (behavioral pain scale [BPS] ≤ 5 or numerical rating score [NRS] ≤ 3) was achieved by escalating the dose in 1 mL/h increasing. Administration was then adjusted to maintain the target level of analgesia until weaning from the ventilator. The primary endpoint was the proportion of patients who did not require rescue fentanyl. Safety was assessed according to standard procedures. PK of remifentanil in the arterial blood was assessed in 24 patients.
RESULTS: The proportion of patients achieving the primary endpoint in the remifentanil and fentanyl groups was 100% (92/92) and 97.8% (88/90), respectively. The difference between the groups was 2.2% (95% confidence interval, - 0.8-5.3) and non-inferiority of remifentanil to fentanyl was verified (p < 0.0001). The incidences of any adverse events in the remifentanil and fentanyl groups was 34 of 92 patients (37.0%) and 34 of 90 patients (37.8%), respectively. Adverse drug reactions was 12 in 92 patients (13.0%) and 15 in 90 patients (16.7%), respectively. In the PK analysis, blood remifentanil concentration decreased within 10 min to almost 50% of the end of administration, suggesting rapid offset of action following discontinuation of remifentanil.
CONCLUSIONS: Remifentanil can be used safely for pain management in mechanically ventilated Japanese patients in the ICU.
TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCT2080224954. Registered 20 November 2019, https://jrct.niph.go.jp/latest-detail/jRCT2080224954 .
参考来源
- Doi M, Takahashi N, Nojiri R, et al. Efficacy, safety, and pharmacokinetics of MR13A11A, a generic of remifentanil, for pain management of Japanese patients in the intensive care unit: a double-blinded, fentanyl-controlled, randomized, non-inferiority phase 3 study. J Intensive Care. 2023. PMID: 37953283. doi:10.1186/s40560-023-00698-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。